Vertex Pharmaceuticals, Inc. (VRTX) Misses Q2 EPS by 13c; Revises Revenues
Tweet
Share
E-mailGet Alerts VRTX Hot Sheet
Price: $508.34 -1.55%
Revenue Growth %: +10.7%
Financial Fact:
Net loss: -39.54M
Today's EPS Names:
VIVO, OCCI, ALZN, More
Revenue Growth %: +10.7%
Financial Fact:
Net loss: -39.54M
Today's EPS Names:
VIVO, OCCI, ALZN, More
Join SI Premium – FREE
Vertex Pharmaceuticals, Inc. (NASDAQ: VRTX) reported Q2 EPS of $0.46, $0.13 worse than the analyst estimate of $0.59. Revenue for the quarter came in at $418.3 million versus the consensus estimate of $472.16 million.
Vertex today revised guidance for full-year 2012 INCIVEK net revenues. The company expects full-year 2012 INCIVEK net revenues to be in the range of $1.1 billion to $1.25 billion. The revised guidance reflects the recent downward trend in the number of patients initiating treatment within the hepatitis C market.
For earnings history and earnings-related data on Vertex Pharmaceuticals, Inc. (VRTX) click here.
Vertex today revised guidance for full-year 2012 INCIVEK net revenues. The company expects full-year 2012 INCIVEK net revenues to be in the range of $1.1 billion to $1.25 billion. The revised guidance reflects the recent downward trend in the number of patients initiating treatment within the hepatitis C market.
For earnings history and earnings-related data on Vertex Pharmaceuticals, Inc. (VRTX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Westinghouse said to seek over $50 billion valuation in planned IPO
- Redburn upgrades Southwest, stays bullish on Delta and United
- Lumentum shares rise on analyst upgrades, AI demand outlook
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
